30 results about "Intermediary metabolite" patented technology

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.

The invention provides a kit and a test method for detecting catecholamine intermediate metabolites in human plasma, and the kit comprises the following reagents: (1) a calibrator solution, which is divided into calibrators with six concentrations, the calibrator with each concentration contains three catecholamine intermediate metabolites: methoxyepinephrine, methoxynoradrenaline and 3-methoxytyramine, and the calibrator solution is a solution of calibrators with six concentrations; the concentration of the calibration product is 10 pg / mL to 4000 pg / mL; (2) quality control products including a quality control product QCL, a quality control product QCM and a quality control product QCH; (3) an internal standard solution, namely a methanol solution mixed solution containing intermediate metabolites of three catecholamines; (4) a buffer solution I and a buffer solution II; (5) preparing a derivative solution; (6) leacheate; (7) an eluent; (8) a 96-hole purification plate and a 96-hole receiving plate; and (9) covering a 96-well plate with a film. The sample is treated by solid-phase extraction and then derivatization reaction, so that the detection sensitivity of the catecholamine intermediate metabolite in the sample is improved.

The present invention provides a photobiological ethanol production and harvesting technology using greenhouse distillation systems with designer photosynthetic organisms, such as designer transgenic oxyphotobacteria. The designer oxyphotobacteria are created such that the endogenous photobiological regulation mechanism is tamed, and the reducing power (NADPH) and energy (ATP) acquired from the photosynthetic process are used for synthesis of ethanol (CH3CH2OH) directly from carbon dioxide (CO2) and water (H2O). The designer use of a pair of NADPH-dependent vs. NAD-dependent glyceraldehyde-3-phosphate dehydrogenases in the pathway designs offers a special cyclic “transhydrogenase” redox-shuttle function to convert NADPH to NADH for enhanced photobiological ethanol production. Through combined use of a designer photosynthetic organism with a greenhouse distillation system, the waste solar heat associated with the photobiological ethanol-production process is utilized in harvesting the produced ethanol. In addition to production and harvesting of ethanol, use of the technology can also produce intermediate metabolites and freshwater from seawater.

It is an object of the present invention to provide a bacterial strain that can decrease the amount of an intermediate Compound P converted into Metabolite M and efficiently accumulate Compound P in a medium that is not supplemented with Metabolite M or the final product generated from Metabolite M. The present invention provides a prokaryotic organism having all features (a) to (d) as defined in the specification so as to accumulate Compound P by regulating expression level of Enzyme X that converts Compound P as an intermediate metabolite into Metabolite M in a biosynthetic pathway in which Metabolite M indispensable for the growth is produced from a carbon source.

The invention provides a method for producing 1,3-propylene glycol with a fed-batch, and comprises a standard preparation method for seeds, followed by fermentation and cultivation. During fermentation, the relational function on the consumed dosage between the medium metabolite neutralizer and the substrate is used to control the concentration of the substrate (glycerol) in the fermentation liquid within a certain range, through adding the dosage of the substrate based on the feedback linkage with the consumed dosage of the medium metabolite neutralizer, so that neither substrate inhibition nor scarcity appears. The method can accomplish accurate feedback control on the substrate concentration of the fermentation liquid through monitoring the consumed dosage of the medium metabolite neutralizer, thereby increasing the yield of 1,3-propylene glycol. Control with singlechip or computer can be carried out during fermentation, with manual or automatic manipulation, while the investment is low with both simple operation and suitability for industrialized production.

The invention discloses an anti-blocking liquid used in surgery and a method for preparing the same. The anti-blocking liquid comprises 1 weight% carboxymethyl chitosan having molecular weight of 200000-300000 dalton and 30-100 weight% water for injection, which dynamics viscosity is 100~800 centipoise. The preparing method comprises: removing impurity protein pyrogen from the raw material; carboxymethyl-modification of chitin; purifying the carboxymethyl chitosan; preparing the anti-blocking liquid and the preparation thereof. Accordingly, the anti-blocking liquid has excellent biological barrier performance and histocompatibility, after applied on tissue wound surface, can prevent tissue tissue adhesion postoperation, which intermediary metabolite and final metabolite in human body are normal metabolites facilitating to be absorbed by the human body, without toxicity and acrimony. The anti-blocking liquid has abundance material sources with low cost and simple process, thus has broad application prospects in clinical medicine art.

The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.Enz-64

The invention discloses a kit for detecting a monohydroxyphenol metabolite in urine. The kit comprises an ampoule bottle accommodated with a detection reagent, wherein the detection reagent is chitosan compound cellulose aerogel adsorbed with a color development mixture. A preparation method comprises the following steps: preparing chitosan-cellulose-chitosan aerogel hierarchically, and then adsorbing tyrosinase, tryptophanase and a color development reagent which can react with an intermediate metabolite obtained by decomposing tyrosine and tryptophan and develop a color to the aerogel through an enzyme fixing method. The kit has a specificity detection function for the trace monohydroxyphenol metabolites in the urine, and a detection method is simple, quick and high in accuracy.

Provided are polynucleotides of molecular variant promoters of the CYP2D6 gene which, for example, are associated with abnormal drug response or individual predisposition to several common diseases and disorders caused by drug under- or over-metabolization, and vectors comprising such polynucleotides. Furthermore, methods of diagnosing the status of disorders related to intermediate metabolization of drugs are described. In addition, kits comprising oligonucleotides hybridizing to the CYP2D6 promoter and / or being capable of being extended into this region useful for diagnosing subjects that are ultrarapid or intermediate metabolizer of drugs are provided.

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.

Pyruvic acid is the important intermediary metabolite in biologic sugar metabolism. It has sanitarian effect and is the material of synthesizing products such as L- tryptophan, L-tyrosine and L- DOPA. This invention is a kind of method of producing pyruvic acid by dermoid hyphomycosis yeast to ferment glucose. It can get more than 40g per litre pyruvic acid from simple culture medium without adding vitamin and amino acid.

The invention discloses an anti-blocking gel used in surgery and a method for preparing the same. The anti-blocking gel comprises 1 weight% carboxymethyl chitosan having molecular weight of 300000-700000 dalton and 20-30 weight% water for injection, which dynamics viscosity is 800~3000 centipoise. The preparing method comprises: removing impurity protein pyrogen from the raw material; carboxymethyl-modification of chitin; purifying the carboxymethyl chitosan; preparing the anti-blocking gel and the preparation thereof. Accordingly, the anti-blocking gel has exellent biological barrier performance and histocompatibility, after applied on tissue wound surface, can prevent tissue tissue adhesion postoperation, which intermediary metabolite and final metabolite in human body are normal metabolites facilitating to be absorbed by the human body, without toxicity and acrimony. The anti-blocking gel has abundance material sources with low cost and simple process, thus has broad application prospects in clinical medicine art.

It is an object of the present invention to provide a bacterial strain that can decrease the amount of an intermediate Compound P converted into Metabolite M and efficiently accumulate Compound P in a medium that is not supplemented with Metabolite M or the final product generated from Metabolite M. The present invention provides a prokaryotic organism having all features (a) to (d) as defined in the specification so as to accumulate Compound P by regulating expression level of Enzyme X that converts Compound P as an intermediate metabolite into Metabolite M in a biosynthetic pathway in which Metabolite M indispensable for the growth is produced from a carbon source.

The invention relates to the technical field of synthetic biology, in particular to a genetic element, an expression vector and application of the genetic element and the expression vector. The invention provides a novel method for improving the synthesis of fatty hydrocarbon microorganisms: the fatty hydrocarbon synthesis capability of escherichia coli is improved by dynamically balancing accumulation and conversion of a key intermediate metabolite, namely fatty aldehyde. In order to achieve this purpose, ADO is helped to balance the synthesis and conversion of the fatty aldehyde through a competition path by synergistically expressing a synthesis process of fatty alcohol; then, three modules for fatty acid synthesis, lipid degradation and electron transfer, which are related to dynamic balance of the fatty aldehyde, are matched with a fatty hydrocarbon synthesis module, and finally the artificial synthesis of high-yield fatty hydrocarbon from engineering escherichia coli is realized.

The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.

The invention discloses a concentration response type biochemical multi-component online analyzer. The concentration response type biochemical multi-component online analyzer comprises a multi-component concentration detection module, a precise sampling mechanical arm, a multi-channel data acquisition module, an automatic sampling module and a multi-channel flow path structure; the multi-componentconcentration detection module is composed of a detection pool, a sample pool, a sampling pool, a cleaning pool and a waste liquid pool, and can realize online detection on multi-component concentration; the sampling mechanical arm is composed of a two-freedom-degree mechanism arm, a precision syringe and a sample injection needle, and realizes precise locating sampling control on the detection pool; the multi-channel data acquisition module is composed of an embedded development board and a touch screen, and realizes online detection, display and storage on the multi-component concentration;the automatic sampling module is composed of a precision membrane sampler, a miniature vacuum diaphragm pump and a stop valve; and the four parts are linked and assembled through a multi-channel flowpath integrated structure. According to the concentration response type biochemical multi-component online analyzer disclosed by the invention, online real-time detection on multiple substrates, keyintermediate metabolites and product concentrations in a microbial fermentation process can be realized; the structure is compact; and batch production is conveniently carried out.

The invention provides a recombinant Bacillus subtilis, construction method and use thereof, wherein the cell's own FMMs are used as a space scaffold, and a multi-enzyme complex is constructed from specific marker proteins FloA and FloT, such that an artificial substrate channel is formed, and the cell metabolic burden is effectively reduced. The recombinant Bacillus subtilis of the invention can efficiently synthesize GlcNAc without affecting cell life activity, and can also limit the toxic intermediate metabolite GlcN-6-P near the plasma membrane to reduce or eliminate its inhibition on cell activity. In the process of shaking flask fermentation using complex medium, the yield of acetyl glucosamine of the control strain BSG-C was only 0.45 g·L−1, while that of BSG-AT, BSG-ATP, BSG-ATPB increased to 5.29 g·L−1, 6.22 g·L−1 and 8.48 g·L−1 respectively. The construction method of recombinant Bacillus subtilis is simple, easy to use and has a good application prospect.